곧옵니다!     Goordhow Filo!     በቅርብ ቀን!     Malapit na!     አብ ቀረባ እዋን!     持续更新中!     جلد آرہے ہیں!

Our Network Partners

Greater Seattle Coronavirus Assessment Network (SCAN) Update: June 10, 2020



SCAN is re-launching on Wednesday, June 10th, while upholding the spirit of #ShutDownSTEM. The study’s researchers move forward with their work, including outreach to underserved communities and protesters, and recognize the disproportionate impact that COVID-19 is having on Black communities and other people of color, with devastating consequence. Black Lives Matter. The team stands with those across the United States fighting racial injustice.

The greater Seattle Coronavirus Assessment Network (SCAN) will resume testing of home-based, self-collected samples for COVID-19 on June 10, 2020.

SCAN will resume operations as a research study with institutional review board (IRB) approval and oversight from the University of Washington, Seattle Children’s, and Fred Hutchinson Cancer Research Center. The program continues to pursue an Emergency Use Authorization (EUA) from the Food & Drug Administration (FDA).

SCAN’s sample collection and testing processes, research and analysis capabilities, institutional partnerships, and operational mission to support King County’s public health response remain unchanged. In this next phase, SCAN will make more tests available to under-represented communities, individuals at higher risk of contracting COVID-19, children under 18 years of age, and family members and close contacts of SCAN participants who test positive for the virus. New SCAN participants will also complete a longer consent form when signing up, which is a required practice for participation in research studies.

There are no concerns about the safety or accuracy of SCAN’s test. The program has submitted data to the FDA validating the safety of the nasal swabs it uses to collect samples, shipping and specimen stability for samples sent in by mail, and the reliability of SCAN’s diagnostic test. The data reflects evidence gathered from testing more than 17,000 home-collected samples through both the Seattle Flu Study and SCAN. This data has been reviewed by the Washington State Department of Health and is currently under review by the FDA.

SCAN is unfortunately unable to return test results for samples submitted prior to the May 12th pause. Although the IRB has authorized SCAN to move forward as a research study, allowing for both COVID-19 testing and return-of-results, it is not within the board’s purview to provide retroactive approval for previously submitted samples. The team understands this is frustrating and will contact impacted individuals directly with more information.

New SCAN participants are invited to enroll via our website. Please note that daily enrollment is limited.